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OBJECTIVE: to estimate the costs and effects of clo-
dronate vs placebo in prevention of bone complications
in metastatic breast cancer in Poland. METHODS: The
model for the Polish health care context was developed,
based on the use of clinical data from literature and local
data on health care resource utilization and unit cost.
Only direct medical costs are analyzed. The perspective
of health-care payers and time horizon of 18 months
were taken. In the cost-effectiveness analysis the primary
clinical outcomes for measuring success in the analysis
were the avoided skeletal related events (SRE), which
were defined as pathological fractures, irradiation and
episodes of hypercalcaemia. The one-way sensitivity analysis
and threshold analysis were performed. RESULTS: The
costs of avoiding of SRE for clodronate vs placebo was
5292–5404 PLN. This value was lower then costs of
treatment of pathological fractures (7,000–40,000 PLN) and
higher than treatment of hypercalcaemia or irradiation
episode (2,200–2,600 PLN). The results were most sensi-
tive to the costs of treatment of pathologic fractures and
number of SRE avoided. CONCLUSION: Clodronate
therapy for advanced breast cancer offers substantial
benefit at a reasonable cost to the Polish health care sys-
tem, but in comparison to pamidronate is less cost-effective.
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OBJECTIVE: The purpose of this study was to estimate
the payer costs of pancreatic cancer for a nonelderly
Medicaid population and to provide a breakdown of
costs by type of care. METHODS: We performed a retro-
spective analysis of California Medicaid (Medi-Cal) data
linked by encrypted social security number to the Califor-
nia Department of Health Services Vital Statistics data-
base. We limited the sample to patients who were contin-
uously enrolled in Medi-Cal from six months prior to
their first pancreatic cancer diagnosis through death or
through December 31, 1998, whichever occurred first.
Patients must have had at least two diagnoses of pancre-
atic cancer or one diagnosis and a cause of death of pan-
creatic cancer. We excluded elderly patients (65 years)
because most of their medical bills are paid by Medicare
not Medicaid, which is a limitation in these data. We esti-
mated costs using the Kaplan-Meier Sample Average,
which results in consistent cost estimates if the censoring
mechanism is independent of survival and cost, a condi-
tion that is satisfied in the present analysis. All cost esti-
mates were expressed in 1999 U.S. dollars. RESULTS: Of
410 Medi-Cal patients meeting the study inclusion crite-
ria, the mean cost per patient for all services was $19,191.
The mean inpatient facility cost (including inpatient che-
motherapy) was $11,435 (59.6% of total costs) and the
mean cost of outpatient clinic visits was $2,416 (12.6%
of total costs). The mean cost of hospital outpatient visits
and hospice care was $828 (4.3% of total costs) and
$1,096 (5.7% of total costs), respectively. The mean cost
of outpatient chemotherapy agents was just $178 (0.9%
of total costs). Only 105 patients (25.6% of our sample)
received outpatient chemotherapy. CONCLUSION: This
analysis presents estimates of the payer cost of pancreatic
cancer among nonelderly Medi-Cal patients. Similar ex-
amination of costs among elderly patients is warranted.
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OBJECTIVE: To quantify and characterize trends in out-
patient pharmaceutical expenditures in-patients diagnosed
with cancer. METHODS: Medical and pharmaceutical
costs (claims) from a large US managed care population
were utilized. Members with a confirmed diagnosis of
cancer were identified for the years 1995 and 1998.
Transaction costs were compiled for all outpatient drugs,
and compared between years. Drugs were grouped into
four categories: (1) chemotherapy; (2) chemotherapy ad-
juncts (i.e., drugs which enhanced or extended chemo-
therapy treatment); (3) supportive therapy (i.e., drugs to
treat complications or symptoms related to cancer); and
(4) drugs for routine patient conditions unrelated to can-
cer. RESULTS: There were $17.9 million in claims for
drugs in 1995, rising to $27.9 million in 1998, an in-
crease of over $10 million. Chemotherapy was the largest
driver of the cost increase, representing 52.4% of the to-
tal increase ($5.3 million). Routine patient drugs unre-
lated to their cancer therapy were the second most im-
portant cost driver, accounting for 31% of the increase
($3.1 m). Supportive therapies were third, and accounted
for 12% of the total increase ($1.2 m): among this group,
antidepressants showed the largest increase in cost, fol-
lowed by gastrointestinal agents and analgesics. Chemo-
therapy adjuncts as a class had the smallest impact on to-
tal cost increases—4.8% of the total increase, or $0.5
